Abstracts Archive - Page 2017 of 2607 - ACR Meeting Abstracts

Abstract Number: 2194 • 2015 ACR/ARHP Annual Meeting
Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome
Alina Casian¹, Shirish Sangle (joint 1st author)², Sotiria Manoustathopoulou³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, UK, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Department of Medicine, St. Thomas' Hospital, London, United Kingdom, ⁴Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: Our previous data showed renal artery stenosis (RAS) is more prevalent in antiphospholipid syndrome(APS)(26%) compared to the general hypertensive population(8%),and anticoagulation with INR>=3 was…
Abstract Number: 2195 • 2015 ACR/ARHP Annual Meeting
Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study
Francesca Dall'Ara¹, Mara Taraborelli², Rossella Reggia¹, Micaela Fredi², Maria Gerosa³, Laura Massaro⁴, Ariela Hoxha⁵, Marta Tonello⁵, Patrice Cacoub⁶, Nathalie Costedoat-Chalumeau⁷, Franco Franceschini², Pier Luigi Meroni⁸, Jean Charles Piette⁶, Amelia Ruffatti⁵, Guido Valesini⁴ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, ⁴Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁸Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy
Background/Purpose: Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients (pt) are still very limited.The objectives of this work was to assess the…
Abstract Number: 2196 • 2015 ACR/ARHP Annual Meeting
Association Between Antiphospholipid Antibodies and All-Cause Mortality Among End Stage Renal Disease Patients with and without SLE
Anna R. Broder¹, Wenzhu Mowrey², Mimi Kim³, Irina Murakhovskaya⁴, Joel Neugarten⁵, Karen H. Costenbader⁶ and Chaim Putterman⁷, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Department of Epidemiology and Population Health/Division of Biostatistics, Albert Einstein College of Medicine, Bronx, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Medicine/Hametology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁵Medicine/Nephrology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁶Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: We investigated the association between the presence of antiphospholipid antibodies (aPL) and/or lupus anticoagulant (LAC) (aPL/LAC+) and all-cause mortality among end stage renal…
Abstract Number: 2197 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholip Antibodies-Positive Women According to Different Treatment Protocols: A Single Center Experience over 30 Years
Maria Grazia Lazzaroni¹, Laura Andreoli¹, Fabrizio Lupoli¹, Elena Aggogeri¹, Elisa Bettiga², Sonia Zatti², Andrea Lojacono², Francesca Ramazzotto², Micaela Fredi³, Cecilia Nalli⁴, Rossella Reggia¹, Francesca Dall'Ara¹, Mara Taraborelli³, Roberto Gorla³, Matteo Filippini³, Marco Taglietti³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). Risk stratification may include several demographic, clinical and serological variables. Still debated is…
Abstract Number: 2198 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Clinical Database and Repository Analysis: Determinants of Thrombosis in Patients Presenting with Obstetric APS
Guilherme Ramires de Jesus¹, STEPHANE ZUILY², Doruk Erkan³, Roger A. Levy⁴ and on Behalf of APS ACTION, ¹Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose: APS ACTION Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive…
Abstract Number: 2199 • 2015 ACR/ARHP Annual Meeting
in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Francisco Velasco², Patricia Ruiz-Limon¹, Nuria Barbarroja¹, Yolanda Jiménez Gómez¹, Maria Carmen Abalos-Aguilera¹, Pedro Segui³, Eduardo Collantes-Estevez¹, Lucia Fernandez-del Rio⁴, Jose Antonio Gonzalez-Reyes⁴, Jose Manuel Villalba⁴, Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, ³IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain, ⁴Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: To investigate the beneficial effects of in vivoubiquinol (Q, reduced form of CoQ10) supplementation on athero-thrombosis prevention in APS patients, through the implementation of…
Abstract Number: 2200 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients
Stephane Zuily¹, Cecilia B. Chighizola², DENIS WAHL¹, Pier Luigi Meroni³ and Doruk Erkan⁴, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ²Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, ³University of Milan, Department of Clinical Sciences and Community Health, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, ⁴Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of persistently antiphospholipid antibodies (aPL)-positive patients ± autoimmune disorders over…
Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting
Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers
Cécile Yelnik^1,2, Elodie Drumez³, Sylvain Dubucquoi^2,4,5, Vincent Sobanski^1,2,4, Hélène Maillard^1,6, Alain Duhamel³, David Launay^1,2,4, Eric Hachulla^1,2,4, Pierre-Yves Hatron^1,2 and Marc Lambert^1,2,4, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³CERIM, Université Lille Nord de France, Lille, France, ⁴LIRIC, INSERM UMR 995, Lille, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France
Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…
Abstract Number: 2202 • 2015 ACR/ARHP Annual Meeting
Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-Beta-2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with SLE – Associations with Different Clinical Outcomes
Amrita D'Souza¹, Charis Pericleous², Oliver Leach¹, Karim Fouad Alber¹, Thomas McDonnell², Yiannis Ioannou², Ian Giles³, David A. Isenberg⁴ and Anisur Rahman⁵, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Rayne Intitiute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical sequelae including vascular events (VE) and pregnancy morbidity (PM).…
Abstract Number: 2203 • 2015 ACR/ARHP Annual Meeting
Loss of Wdfy3 Leads to Enhanced Osteoclastogenesis Via NF-κB Activation
Dennis J. Wu^1,2, Ran Gu², Ritu Sarin², Regina Zavodovskaya³, Chia-Pei Chen⁴, Konstantinos Zarbalis^5,6 and Iannis E. Adamopoulos^1,2,6, ¹Graduate Group in Immunology, University of California, Davis, Davis, CA, ²Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA, ³Department of Anatomy, Physiology and Cell Biology, University of California, Davis, Davis, CA, ⁴Department of Statistics, University of California, Davis, Davis, CA, ⁵Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, ⁶Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Northern California, Sacramento, CA
Background/Purpose: Autophagy and phagocytosis are conserved cellular functions involved in the protein degradation process in immunity. Recently, autophagy-related proteins were shown to regulate osteoclast mediated…
Abstract Number: 2204 • 2015 ACR/ARHP Annual Meeting
Tankyrase Regulates Osteoclastogenesis Via SH3BP2 Expression
Tomoyuki Mukai, Shunichi Fujita, Takafumi Mito, Akiko Nagasu, Yumi Sasae, Hiroyasu Hirano and Yoshitaka Morita, Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan
Background/Purpose: SH3BP2, an adaptor protein, is dominantly expressed in immune cells including macrophages and regulates intracellular signaling pathways. Gain-of-function mutations in SH3BP2 cause human genetic…
Abstract Number: 2205 • 2015 ACR/ARHP Annual Meeting
Inhibition of Dickkopf1 Dampens Anti Osteogenic Effect of Fibroblast-like Synoviocytes
Eiji Sugiyama, Yusuke Yoshida and Satoshi Yamasaki, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Fibroblast-Like Synoviocytes (FLS) play important roles in RA progression. Previous studies have revealed importance of FLS in osteoclast activation, however, the roles of…
Abstract Number: 2206 • 2015 ACR/ARHP Annual Meeting
Dopamine Pathway and Bone Metabolism in Arthritis
Silvia Capellino¹, Klaus W. Frommer¹, Markus Rickert², Jürgen Steinmeyer³, Stefan Rehart⁴, Ulf Müller-Ladner¹ and Elena Neumann¹, ¹Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²Dept of Orthopedics and Orthopedic Surgery, University Hospital of Giessen and Marburg, Gießen, Germany, ³Dept Orthopedics and Experimental Orthopedics, University Hospital of Giessen and Marburg, Giessen, Germany, ⁴Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany
Background/Purpose: A body of studies demonstrates the influence of the nervous system on the immune response. We recently described that dopamine, a neurotransmitter of the…
Abstract Number: 2207 • 2015 ACR/ARHP Annual Meeting
Interleukin-32Î³ Exhibited Protective Effects on Osteoporosis
Seokchan Hong¹, Eun-Jin Lee², Sang-Min Kim³, Eun-Ju Chang², Doo-Ho Lim⁴, Byeongzu Ghang⁵, Wookjang Seo⁶, Yong-Gil Kim⁴, Chang-Keun Lee¹ and Bin Yoo⁴, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁶Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Interleukin-32 (IL-32) has been known to be implicated in the pathogenesis of various inflammatory diseases. Osteoporosis, characterized by low bone density and increases the…
Abstract Number: 2208 • 2015 ACR/ARHP Annual Meeting
Macrophage Migration Inhibitory Factor: A Novel Biomarker in Ankylosing Spondylitis That Can Drive Spinal Fusion
Vidya Ranganathan¹, Ismail Sari², Janogini Muralitharan³, Ammepa Anton⁴ and Nigil Haroon², ¹University Health Network, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that predominantly affects the axial skeleton. Disease progression in AS is marked by new bone formation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].